Share price · NAMS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NAMS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+8.0%
Nothing announced by NAMS that day or the session before.
- 23 Oct 2026-8.7%
Nothing announced by NAMS that day or the session before.
- 9 Sep 2026-11.1%
Nothing announced by NAMS that day or the session before.
- 8 May 2026+11.1%
- 7 May 2026+12.5%
- 14 Apr 2026-5.0%
Nothing announced by NAMS that day or the session before.
- 2 Mar 2026-7.4%
- 3 Dec 2025-7.3%
Nothing announced by NAMS that day or the session before.
Share of unusual movement by asset
For each asset, the share of NAMS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CETPSmall molecule | Type 2 DiabetesAtherosclerotic Cardiovascular DiseaseAlzheimer's Disease Early Alzheimer's Disease | |
| Phase 3 | CETP · NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $19M | $39M | $423M+ $205M short-term inv. | $17M-$40M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.7M | $42M | $424M+ $210M short-term inv. | $64M-$39M operating cash flow | report ↗ |
| 2026-Q1 | $3.0M | $38M | $458M+ $179M short-term inv. | $48M-$31M operating cash flow | report ↗ |
| 2025-Q3 | $0.3M | $31M | $538M+ $165M short-term inv. | $72M-$33M operating cash flow | report ↗ |
| 2025-Q2 | $19M | $28M | $564M+ $175M short-term inv. | $17M-$38M operating cash flow | report ↗ |
| 2025-Q1 | $3.0M | $45M | $748M+ $60M short-term inv. | $40M-$36M operating cash flow | report ↗ |
| 2024-Q3 | $29M | $36M | $423M | $17M-$13M operating cash flow | report ↗ |
| 2024-Q2 | $2.3M | $38M | — | $39M-$54M operating cash flow | report ↗ |
| 2024-Q1 | $1.4M | $42M | — | $94M-$55M operating cash flow | report ↗ |
| 2023-Q3 | $2.9M | $43M | — | $47M-$47M operating cash flow | report ↗ |
| 2023-Q2 | $1.7M | $34M | — | $38M-$29M operating cash flow | report ↗ |
| 2023-Q1 | $8.6M | $40M | — | $42M-$32M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $23M | $142M | $490M+ $146M short-term inv. | $51M-$148M operating cash flow | report ↗ |
NewAmsterdam Pharma reported full-year 2025 revenue of $22.5M, down 50.6% YoY, with R&D expenses of $141.83M, down 6.3% YoY. The company ended the year with $490M in cash and cash equivalents, or $728.9M including marketable securities, and reported a net loss of $203.82M.
Management guided to approval decisions from EMA, UK and Switzerland regulators for obicetrapib and the fixed-dose combination expected in the second half of 2026, topline data from the Phase 3 RUBENS trial by year-end 2026, and a planned new clinical trial in early Alzheimer’s disease patients in 2026. The blinded MACE event rate in the Phase 3 PREVAIL cardiovascular outcomes trial through the initial 12 months was in line with the BROADWAY trial, and cash runway is expected to fund operations through the PREVAIL readout and, if approved, support a subsequent U.S. commercial launch.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $46M | $151M | $772M+ $62M short-term inv. | $60M-$159M operating cash flow | report ↗ |
| 2023-FY | $14M | $159M | $340M | $44M-$141M operating cash flow | report ↗ |
| 2022-FY | $103M | $87M | — | $5.7M$11M operating cash flow | report ↗ |
| 2021-FY | — | $29M | — | $10M-$30M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($227K), 43 sales ($63.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter · director, Chief Scientific Officer | Option exercise | 50,246 | — | — | Form 4 |
| 2026-09-30 | Kastelein Johannes Jacob Pieter · director, Chief Scientific Officer | Open-market sale | 50,246 | $25.03 | $1.3M | Form 4 |
| 2026-09-30 | Kastelein Johannes Jacob Pieter · director, Chief Scientific Officer | Option exercise (derivative) | 50,246 | — | — | Form 4 |
| 2026-09-14 | Davidson Michael H. · director, Chief Executive Officer | Open-market purchase | 10,000 | $22.65 | $227K | Form 4 |
| 2026-09-04 | Smither John W · director | Open-market sale | 1,600 | $25.32 | $41K | Form 4 |
| 2026-09-01 | Gunning Robert William · Vice President, Controller | Award / grant | 3,200 | — | — | Form 4 |
| 2026-09-01 | Gunning Robert William · Vice President, Controller | Award / grant (derivative) | 14,000 | — | — | Form 4 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter · director, Chief Scientific Officer | Option exercise | 125,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 167 reporting institutions held 123.1M shares ($3.8B, 105.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 16,943,774 | $542.4M |
| 2 | Capital World Investors | 11,109,034 | $355.6M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 9,550,191 | $305.7M |
| 4 | FCPM III SERVICES B.V. | 9,198,900 | $294.5M |
| 5 | FMR LLC | 8,765,811 | $280.6M |
| 6 | Bain Capital Life Sciences Investors, LLC | 7,306,566 | $233.9M |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 5,115,818 | $163.8M |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4,264,789 | $136.5M |
| 9 | VIKING GLOBAL INVESTORS LP | 4,203,567 | $134.6M |
| 10 | Polar Capital Holdings Plc | 2,831,607 | $90.6M |
| 11 | JENNISON ASSOCIATES LLC | 2,750,403 | $88.0M |
| 12 | Medicxi Ventures Management (Jersey) Ltd | 2,674,182 | $85.6M |
| 13 | JANUS HENDERSON GROUP PLC | 2,258,984 | $72.3M |
| 14 | WESTFIELD CAPITAL MANAGEMENT CO LP | 2,202,913 | $70.5M |
| 15 | MAVERICK CAPITAL LTD | 2,186,402 | $70.0M |